← Oncology Approval Tracker

FDA DECISION ·

Ryoncil

remestemcel-L-rknd · Mesoblast

FDA approvalNew therapyAcute graft-versus-host disease
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Children aged 2 months and older with steroid-refractory acute graft-versus-host disease.

LAMPGEN ANALYSIS

Why it matters

The allogeneic mesenchymal stromal cell product adds a pediatric rescue option for a serious complication of stem cell transplantation.

What research teams should watch

Record steroid start, dose and response, and coordinate cellular product receipt and infusion with the transplant unit.

PRIMARY RECORDS

Sources